Pegaptanib
Top View
- 5.01.620 Vascular Endothelial Growth Factor (VEGF) Receptor Inhibitors for Ocular Disorders
- Clinical Guideline Preferred Physician-Administered Drugs
- Macugen INN-Pegaptanib Sodium
- For Diabetic Macular Edema a Review of Agents in Clinical Trials
- Beovu (Brolucizumab-Dbll)
- Hpra Drug Safety Newsletter 9499Th Edition
- Lucentis (Ranibizumab) Macugen (Pegaptanib) Visudyne (Pegaptanib) Effective January 1, 2021
- Development of HER2-Specific Aptamer-Drug Conjugate for Breast
- Effect of Sunitinib in Treatment of Retinal Angiogenesis Induced by VEGF165 in Rabbit’S Eyes
- Perioperative Medication Management - Adult/Pediatric - Inpatient/Ambulatory Clinical Practice Guideline
- Medical Benefit Injectable Drugs | Kaiser Permanente Washington
- Silverback Care Management CARE N' CARE Specialty Drug
- Ranibizumab and Pegaptanib for the Treatment of Age-Related Macular Degeneration Vol
- Structural Basis for Vascular Endothelial Growth Factor Receptor Activation and Implications for Disease Therapy
- Specialty Medications - Medical Benefit
- Medical Drug Prior Authorization List
- Macugen® (Pegaptanib)
- National Drug List Drug List — Four Tier Drug Plan